Syphilis Rash on the Body: Appearance, Diagnosis, Treatment

cin3 cervical cancer :: Article Creator

Love Island Star Reveals Terrifying Cancer Scare As She Goes For Biopsy After Warning From Doctors

LOVE Island star Amy Hart revealed her terrifying eye cancer scare to fans as she went for a biopsy - after a warning from her doctor.

The 30-year-old is preparing for the worst and hoping for the best after a cervical biopsy found she had "high grade cells".

Amy Hart had a biopsy after abnormal cells were found in her cervix

She gave birth to her baby boy in MarchCredit: Instagram

That was last year, when the doctor warned her not to get pregnant - shortly before discovering she was expecting.

Having gone back for more tests since giving birth, Amy said she doesn't believe the scan looked any worse than last year.

Updating fans on what happened at her appointment, Amy said: "I did more biopsies today and then I'll have them out at the next procedure.

"If they're not CIN then that's a bonus isn't it?"

red hot Megan Barton Hanson leaves nothing to the imagination as she strips for sunbed

awks Love Island's Faye Winter reveals her most hated villa co-star

CIN stands for Cervical intraepithelial neoplasia, which is usually caused by certain types of human papillomavirus (HPV).

Cervical intraepithelial neoplasia is not cancer, but may become cancer and spread to nearby normal tissue.

Amy couldn't have her high grade precancerous cells removed while pregnant with Stanley because it could result in miscarriage if removed.

In 2021 the reality star spent £12,000 freezing her eggs because of her family's history of early menopause.

Vaginal Intraepithelial Neoplasia: Risk Factors After Hysterectomy For CIN

Months or years after undergoing hysterectomy for cervical intraepithelial neoplasia (CIN), up to 7% of patients are diagnosed with vaginal intraepithelial neoplasia (VaIN).1-4 Although VaIN is uncommon, risk factors for its occurrence post-hysterectomy remain elusive and whether treatment is necessary for low-grade VaIN is unknown.

Take Note

A retrospective investigation suggests that patients older than age 50 years who have undergone hysterectomy for CIN may be at increased risk for VaIN1+.

Laser vaporization may be associated with longer time to second VaIN1+ recurrence versus use of vaginal resection or observation.

For patients who have undergone hysterectomy for CIN – particularly those older than age 50 years – careful and regular follow-up is warranted.

Investigators in South Korea performed a retrospective study to identify risk factors for recurrent VaIN and to evaluate the effects of laser vaporization in patients who underwent hysterectomy as CIN treatment. Their research, published recently in the Journal of Lower Genital Tract Disease, suggests that age older than 50 years may be the only risk factor for VaIN in patients post hysterectomy and that laser vaporization may be the only independent prognostic factor associated with decreased risk for a second VaIN recurrence.5

The primary advantage of their study, the authors noted, was that it "provides useful information" in managing women post hysterectomy for the treatment of CIN. "Furthermore, our results indicate that careful and regular follow-up should be considered in patients who underwent hysterectomy for CIN especially those older than 50 years."

Identifying VaIN risk factors and best possible treatment

Medical records from 374 patients treated for CIN from January 2001 to August 2019 at the Seoul National University Bundang Hospital were used for the study. Those included in the cohort had CIN 1, 2 or 3, carcinoma in situ, or adenocarcinoma and underwent total hysterectomy via either open or minimally invasive approaches. Patients in whom high-grade CIN was diagnosed were considered to have an involved resection margin post procedure.

All of the participants had Pap smears performed 3 to 6 months after hysterectomy. In cases of abnormal cytology, colposcopy-directed biopsy was undertaken. VaIN treatment consisted of ablation with a CO2 laser applied to lesions at the vaginal vault suture line and extending into a dog ear.

The authors assessed the correlation between VaIN1+ recurrence after total hysterectomy and clinicopathologic factors and assessed the relationship between adjuvant treatments (i.E., laser vaporization, vaginal resection, observation alone) and second VaIN1+ recurrence.

The investigators examined factors for VaIN1+ recurrence with multiple regression analysis. Covariates significantly associated with second VaIN1+ recurrence were identified with a Cox proportional hazard regression model. The authors compared relapse-free survival for laser vaporization vs. Observation using Kaplan-Meier survival curves and a log-rank test.

Age >50 years and laser vaporization identified as key variables

At the time of hysterectomies for CIN, patients' median age was 54.4 years. At median follow-up of 32 months, VaIN1+ was found in 36 (9.6%) patients. Of that group, 13 (3.5%) had VaIN1, 6 (1.6%) had VaIN2, 15 (4.0%) had VaIN3, and 2 (0.5%) had invasive cancer. On multivariate analysis age >50 years was found to be an independent risk factor for VaIN1+ recurrence (odds ratio, 3.359; 95% CI, 1.60-7.07; P=.001). The other clinical variables analyzed, including parity, initial histology, human papillomavirus (HPV) 16 or 18, resection margin involvement, or surgical approach to hysterectomy, were not significantly associated with VaIN1+ after hysterectomy.

Laser vaporization was used to treat 21 of 34 of the patients who had VaIN (61.8%), vaginal resection was used in 2 (5.9%), and 11 patients had observation only (32.3%). (Two of the original 36 patients were transferred to other hospitals and lost to follow-up.) Longer time to second recurrence was observed in the treated patients than those who had observation alone (128.7 months vs. 41.8 months; 95% CI, 101.4-156.0 vs 15.7-67.9; P=.003).

Based on Cox regression analysis, the only factor associated with lower risk of a second VaIN+ recurrence was receipt of laser vaporization (hazard ratio, 0.125; 95% CI, 0.03-0.59; P=.009). Kaplan-Meier curves for recurrence-free survival according to treatment modality indicated that patients with VaIN treated by laser vaporization had longer time to second VaIN recurrence compared to those who had been observed without treatment (mean time to second recurrence, in months: 128.7 [95% CI, 101.4–156.0] vs. 41.8 [95% CI, 15.7–67.9]; P=.003).

Perspective on clinical implications

Reflecting on their results and potential impact for clinicians, the authors noted that it can be challenging to decide whether to treat VaIN1, especially when the disease persists. They believe their research shows that laser vaporization may be more effective at reducing second VaIN recurrence than vaginal resection or observation, but offered caveats about the limitations of the analysis.

Rates of HPV, a known risk factor for VaIN and vaginal cancer, were higher in the group with VaIN1+ recurrence (27.8% vs. 15.7%). HPV 16 or HPV 18 positivity, however, was not related to VaIN1+ recurrence, which the authors said may have been due to the small sample size.

"Furthermore," they said in their conclusion, "treatment option was at each physician's discretion, which may induce bias possibly affecting the results of the study because of the retrospective design of the study." The researchers also indicated that the intervals between follow-up observation were uneven and they did not control for the confounding effects of immunosuppressive conditions in each patient because of the cohort's heterogeneity.

Published: May 11, 2023

Judith M. Orvos, ELS, is a medical writer and BELS-certified editor with more than 30 years' experience. Her company, Orvos Communications, LLC, is based in Washington, DC.

Cervical Cancer

Cervical cancer is the term for a malignant neoplasm arising from cells originating in the cervix uteri. One of the most common symptoms of cervical cancer is abnormal vaginal bleeding, but in some cases there may be no obvious symptoms until the cancer has progressed to an advanced stage. Treatment usually consists of surgery (including local excision) in early stages, and chemotherapy and/or radiotherapy in more advanced stages of the disease.

Cancer screening using the Pap smear can identify precancerous and potentially precancerous changes in cervical cells and tissue. Treatment of high-grade changes can prevent the development of cancer in many victims. In developed countries, the widespread use of cervical screening programs has reduced the incidence of invasive cervical cancer by 50% or more.[citation needed]

Human papillomavirus (HPV) infection appears to be a necessary factor in the development of almost all cases (90+%) of cervical cancer. HPV vaccines effective against the two strains of this large family of viruses that currently cause approximately 70% of cases of cervical cancer have been licensed in the U.S, Canada, Australia and the EU. Since the vaccines only cover some of the cancer causing ("high-risk") types of HPV, women should seek regular Pap smear screening, even after vaccination.

The cervix is the narrow portion of the uterus where it joins with the top of the vagina. Most cervical cancers are squamous cell carcinomas, arising in the squamous (flattened) epithelial cells that line the cervix. Adenocarcinoma, arising in glandular epithelial cells is the second most common type. Very rarely, cancer can arise in other types of cells in the cervix.

What is HPV